The U.S multiple myeloma diagnostic market is projected to register a healthy CAGR of 7.8% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
U.S Multiple Myeloma Diagnostic Market, By Disease (Smouldering (Indolent) Multiple Myeloma, Active (Symptomatic) Multiple Myeloma, Solitary Plasmacytoma Of The Bone, Extrameduallry Plasmacytoma, Light Chain Myeloma, Non-Secretory Myeloma And Rare Types Of Myeloma), Test Type (Blood Tests, Urine Tests, Bone Marrow Tests And Cytogenetic Analysis), Type (Devices And Consumables & Reagents), End User (Hospitals, Specialty Clinics, Academic & Research Institutes And Others), Distribution Channel (Direct Tender And Retail Sales) Industry Trends and Forecast to 2027
Some of the major factors contributing to the growth of the U.S multiple myeloma diagnostic market are:
Rising prevalence of multiple myeloma
Government funding to R&D investment for tumor studies
Market Players:
The key market players for U.S multiple myeloma diagnostic market are listed below:
NeoGenomics Laboratories, Inc.
Helena Laboratories Corporation
Bracco Diagnostic Inc.
Cytognos S.L.
ZYTOVISION GmbH
Adaptive Biotechnologies
BioVendor
TriVitron Healthcare
Eurofins Scientific
Quest Diagnostic Incorporated
BD
Invivoscribe, Inc.
BioFluidica
SkylineDx
Siemens Healthcare GmbH
Thermo Fisher Scientific Inc.
Laboratory Corporation of America Holdings
GenPath
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION 11
1.1 OBJECTIVES OF THE STUDY 11
1.2 MARKET DEFINITION 11
1.3 OVERVIEW OF U.S MULTIPLE MYELOMA DIAGNOSTIC MARKET 11
1.4 LIMITATIONS 13
1.5 MARKETS COVERED 13
2 MARKET SEGMENTATION 15
2.1 MARKETS COVERED 15
2.2 GEOGRAPHICAL SCOPE 16
2.3 YEARS CONSIDERED FOR THE STUDY 16
2.4 CURRENCY AND PRICING 16
2.5 DBMR TRIPOD DATA VALIDATION MODEL 17
2.6 MULTIVARIATE MODELLING 20
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 21
2.9 DBMR MARKET POSITION GRID 22
2.10 VENDOR SHARE ANALYSIS 23
2.11 SECONDARY SOURCES 24
2.12 ASSUMPTIONS 24
3 EXECUTIVE SUMMARY 25
4 PREMIUM INSIGHT 28
5 COVID-19 IMPACT ON U.S MULTIPLE MYELOMA DIAGNOSTIC MARKET 29
5.1 PRICE IMPACT 29
5.2 IMPACT ON DEMAND 29
5.3 IMPACT ON SUPPLY CHAIN 30
5.4 STRATEGIC DECISIONS FOR MANUFACTURERS 30
5.5 CONCLUSION 31
6 MARKET OVERVIEW 32
6.1 DRIVERS 34
6.1.1 GOVERNMENT FUNDING AND R&D INVESTMENT FOR TUMOUR STUDIES 34
6.1.2 RISING PREVALENCE OF MULTIPLE MYELOMA IN THE REGION 34
6.1.3 HIGH ADOPTION OF NEW TECHNIQUES 35
6.1.4 RISING OBESE POPULATION 35
6.2 RESTRAINTS 36
6.2.1 LACK OF AWARENESS AND DEARTH OF EXPERTISE 36
6.2.2 HIGH COST OF MULTIPLE MYELOMA DIAGNOSTIC 36
6.3 OPPORTUNITIES 37
6.3.1 ADVANCED HEALTHCARE INFRASTRUCTURE AND REIMBURSEMENTS 37
6.3.2 NEED FOR PERMANENT CURE 37
6.3.3 TECHNOLOGICAL ADVANCEMENT AND RISING CLINICAL STUDIES FOR MANAGEMENT OF MULTIPLE MYELOMA 38
6.4 CHALLENGES 38
6.4.1 RISK INVOLVED DURING TREATMENT OF MYELOMA 38
6.4.2 POOR MANAGEMENT OF MYELOMA 39
7 U.S MULTIPLE MYELOMA DIAGNOSTIC MARKET, BY DISEASE TYPE 40
7.1 OVERVIEW 41
7.2 SMOULDERING (INDOLENT) MULTIPLE MYELOMA 44
7.3 ACTIVE (SYMTOMATIC) MULTIPLE MYLEOMA 44
7.4 SOLITARY PLASMACYTOMA OF THE BONE 44
7.5 EXTRAMEDUALLRY PLASMACYTOMA 44
7.6 LIGHT CHAIN MYLEOMA 45
7.7 NON-SECRETORY MYLEOMA 45
7.8 RARE TYPES OF MULTIPLE MYLEOMA 45
7.8.1 IMMUNOGLOBULIN D (IGD) 46
7.8.2 IMMUNOGLOBULIN E (IGE) 46
8 U.S MULTIPLE MYELOMA DIAGNOSTIC MARKET, BY TEST TYPE 47
8.1 OVERVIEW 48
8.2 BLOOD TEST 51
8.2.1 COMPLETE BLOOD COUNT 51
8.2.2 BETA2-MICROGLOBULIN (<2M) LEVEL TEST 51
8.2.3 CHEMISTRY PROFILE TEST 51
8.2.4 SERUM PROTEIN ELECTROPHORESIS 51
8.2.5 FREELITE SERUM FREE LIGHT CHAIN ASSAY 52
8.2.6 OTHERS 52
8.3 URINE TEST 52
8.3.1 URINE PROTEIN LEVEL TEST 52
8.3.2 URINE PROTEIN ELECTROPHORESIS 52
8.4 BONE MARROW TEST 52
8.4.1 BONE MARROW BIOPSY 53
8.4.2 FINE NEEDLE ASPIRATION BIOPSY 53
8.4.3 CORE NEEDLE BIOPSY 53
8.4.4 IMAGING TESTS 54
8.4.5 CYTOGENETIC ANALYSIS 54
8.5 GENOME SEQUENCING IN MULTIPLE MYELOMA 54
8.5.1 KARYOTYPING 54
8.5.2 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 54
8.5.3 DNA SEQUENCING 55
9 U.S MULTIPLE MYELOMA DIAGNOSTIC MARKET, BY TYPE 56
9.1 OVERVIEW 57
9.2 CONSUMABLES & REAGENTS 60
9.3 DEVICES 60
9.3.1 X-RAY 61
9.3.2 MAGNETIC RESONANCE IMAGING (MRI) 61
9.3.3 COMPUTED TOMOGRAPHY (CT OR CAT) SCAN 61
9.3.4 POSITRON EMISSION TOMOGRAPHY (PET) OR PET-CT SCAN 61
9.3.5 OTHERS 61
10 U.S MULTIPLE MYELOMA DIAGNOSTIC MARKET, BY END USER 62
10.1 OVERVIEW 63
10.2 HOSPITALS 66
10.3 SPECIALTY CLINICS 66
10.4 ACADEMIC AND REASERCH INSITUTES 66
10.5 OTHERS 67
11 U.S MULTIPLE MYELOMA DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL 68
11.1 OVERVIEW 69
11.2 DIRECT TENDER 72
11.3 RETAIL SALES 72
12 U.S. MULTIPLE MYELOMA DIAGNOSTIC MARKET, COMPANY LANDSCAPE 73
12.1 COMPANY SHARE ANALYSIS: U.S 73
13 SWOT ANALYSIS 74
14 COMPANY PROFILE 75
14.1 THERMO FISHER SCIENTIFIC INC. 75
14.1.1 COMPANY SNAPSHOT 75
14.1.2 REVENUE ANALYSIS 75
14.1.3 APPLICATION & TECHNIQUE PORTFOLIO 76
14.1.4 RECENT DEVELOPMENTS 76
14.2 EUROFINS SCIENTIFIC 77
14.2.1 COMPANY SNAPSHOT 77
14.2.2 REVENUE ANALYSIS 77
14.2.3 SERVICE PORTFOLIO 78
14.2.4 RECENT DEVELOPMENTS 78
14.3 BD 79
14.3.1 COMPANY SNAPSHOT 79
14.3.2 REVENUE ANALYSIS 79
14.3.3 PRODUCT PORTFOLIO 80
14.3.4 RECENT DEVELOPMENTS 80
14.4 SIEMENS HEALTHCARE GMBH 81
14.4.1 COMPANY SNAPSHOT 81
14.4.2 REVENUE ANALYSIS 81
14.4.3 PRODUCT PORTFOLIO 82
14.4.4 RECENT DEVELOPMENT 82
14.5 ADAPTIVE BIOTECHNOLOGIES 83
14.5.1 COMPANY SNAPSHOT 83
14.5.2 PRODUCT PORTFOLIO 83
14.5.3 RECENT DEVELOPMENTS 83
14.6 TRIVITRON HEALTHCARE 84
14.6.1 COMPANY SNAPSHOT 84
14.6.2 PRODUCT PORTFOLIO 84
14.6.3 RECENT DEVELOPMENTS 84
14.7 BIOFLUIDICA 85
14.7.1 COMPANY SNAPSHOT 85
14.7.2 PRODUCT PORTFOLIO 85
14.7.3 RECENT DEVELOPMENT 85
14.8 BIOVENDOR 86
14.8.1 COMPANY SNAPSHOT 86
14.8.2 PRODUCT PORTFOLIO 86
14.8.3 RECENT DEVELOPMENT 86
14.9 BRACCO DIAGNOSTIC INC. 87
14.9.1 COMPANY SNAPSHOT 87
14.9.2 PRODUCT PORTFOLIO 87
14.9.3 RECENT DEVELOPMENTS 88
14.10 CYTOGNOS S.L. 89
14.10.1 COMPANY SNAPSHOT 89
14.10.2 PRODUCT PORTFOLIO 89
14.10.3 RECENT DEVELOPMENT 89
14.11 GENPATH 90
14.11.1 COMPANY SNAPSHOT 90
14.11.2 PRODUCT PORTFOLIO 90
14.11.3 RECENT DEVELOPMENTS 90
14.12 HELENA LABORATORIES CORPORATION 91
14.12.1 COMPANY SNAPSHOT 91
14.12.2 PRODUCT PORTFOLIO 91
14.12.3 RECENT DEVELOPMENT 91
14.13 INVIVOSCRIBE, INC. 92
14.13.1 COMPANY SNAPSHOT 92
14.13.2 PRODUCT PORTFOLIO 92
14.13.3 RECENT DEVELOPMENTS 93
14.14 LABORATORY CORPORATION OF AMERICA HOLDINGS 94
14.14.1 COMPANY SNAPSHOT 94
14.14.2 REVENUE ANALYSIS 94
14.14.3 PRODUCT PORTFOLIO 95
14.14.4 RECENT DEVELOPMENT 95
14.15 NEOGENOMICS LABORATORIES, INC. 96
14.15.1 COMPANY SNAPSHOT 96
14.15.2 PRODUCT PORTFOLIO 96
14.15.3 RECENT DEVELOPMENTS 97
14.16 QUEST DIAGNOSTICS INCORPORATED 98
14.16.1 COMPANY SNAPSHOT 98
14.16.2 REVENUE ANALYSIS 98
14.16.3 PRODUCT PORTFOLIO 99
14.16.4 RECENT DEVELOPMENTS 99
14.17 SKYLINEDX 100
14.17.1 COMPANY SNAPSHOT 100
14.17.2 PRODUCT PORTFOLIO 100
14.17.3 RECENT DEVELOPMENT 100
14.18 ZYTOVISION GMBH 101
14.18.1 COMPANY SNAPSHOT 101
14.18.2 PRODUCT PORTFOLIO 101
14.18.3 RECENT DEVELOPMENTS 101
15 QUESTIONNAIRE 102
16 RELATED REPORTS 105
Segmentation
Short Description
U.S Multiple Myeloma Diagnostic Market, By Disease (Smouldering (Indolent) Multiple Myeloma, Active (Symptomatic) Multiple Myeloma, Solitary Plasmacytoma Of The Bone, Extrameduallry Plasmacytoma, Light Chain Myeloma, Non-Secretory Myeloma And Rare Types Of Myeloma), Test Type (Blood Tests, Urine Tests, Bone Marrow Tests And Cytogenetic Analysis), Type (Devices And Consumables & Reagents), End User (Hospitals, Specialty Clinics, Academic & Research Institutes And Others), Distribution Channel (Direct Tender And Retail Sales) Industry Trends and Forecast to 2027
Market Definition:
Multiple myeloma is defined as a cancer of plasma cells. The normal plasma cells are known to be the important part of the immune system. The immune system is made up of different types of cells that help in fighting the infections and other diseases together. Lymphocytes (lymph cells) such as T cells and B cells are the main types of white blood cells presents in the immune system.
Market Segmentation:
The multiple myeloma diagnostic market is segmented on the basis of disease, test type, type, end user and distribution channel.
On the basis of disease, the U.S multiple myeloma diagnostic market is segmented into smouldering (Indolent) multiple myeloma, Active (symptomatic) multiple myeloma, solitary plasmacytoma of the bone, extramedullary plasmacytoma, light chain myeloma, non-secretory myeloma, rare types of multiple myeloma.
On the basis of test type, the U.S multiple myeloma diagnostic market is segmented into blood tests, urine tests, bone marrow tests and genome sequencing in multiple myeloma.
On the basis of type, the U.S multiple myeloma diagnostic market is segmented into devices and consumables & reagents.
On the basis of end user, the U.S multiple myeloma diagnostic market is segmented into hospitals, specialty clinics, homecare, academic and research institutes and others.
On the basis of distribution channel, the U.S multiple myeloma diagnostic market is segmented into direct tender and retail sales.
Market Players
The key market players for the U.S multiple myeloma diagnostic market are listed below:
NeoGenomics Laboratories, Inc.
Helena Laboratories Corporation
Bracco Diagnostic Inc.
Cytognos S.L.
ZYTOVISION GmbH
Adaptive Biotechnologies
BioVendor
TriVitron Healthcare
Eurofins Scientific
Quest Diagnostic Incorporated
BD
Invivoscribe, Inc.
BioFluidica
SkylineDx
Siemens Healthcare GmbH
Thermo Fisher Scientific Inc.
Laboratory Corporation of America Holdings
GenPath
Methodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
